Bone marrow transplantation in chronic granulomatous disease.
A 5-month-old Amish infant boy with chronic granulomatous disease underwent bone marrow transplantation from his 5-year-old, histocompatible brother after a preconditioning regimen of busulfan 2 mg/kg/day for 4 days, followed by cyclophosphamide 50 mg/kg/day for 4 days. At the time of bone marrow transplantation, he was free of infection, and remained so throughout the course of the transplant. He was engrafted promptly, with complete reversal of the neutrophil function defect and no sign of graft-versus-host disease. This was followed by loss of the erythroid graft and deterioration in neutrophil function over a period of 9 months. Sixteen months after transplantation, he is free of infection and growing normally, with essentially no evidence for neutrophil engraftment.
D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D006105:Granulomatous Disease, Chronic / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D006579:Heterozygote; D006801:Humans; D007223:Infant; D008297:Male; D009504:Neutrophils / Q000503:physiopathology; D009580:Nitroblue Tetrazolium; D011292:Premedication
D009580:Nitroblue Tetrazolium; D003520:Cyclophosphamide; D002066:Busulfan